Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.

The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.

What if you'd invested in McKesson (MCK) ten years ago? It may not have been easy to hold on to MCK for all that time, but if you did, how much would your investment be worth today?

McKesson's Business In-Depth

With that in mind, let's take a look at McKesson's main business drivers.

McKesson Corporation, headquartered in Irving, TX, is one of the largest global healthcare companies and the leading pharmaceutical distributor in North America. The company operates across four business segments: U.S. Pharmaceutical, which distributes branded, generic, and specialty drugs; RxTS, which provides patient access, affordability, and third-party logistics services for biopharma manufacturers and payors; Medical-Surgical Solutions, supplying alternate-site providers such as physician offices and home health; and International, primarily focused in Canada. Specialty pharmaceuticals, oncology services, and GLP-1 medications for diabetes and obesity are key growth engines. In FY25, GLP-1 revenues alone reached nearly $41 billion.

McKesson is streamlining its portfolio. It has completed the sale of Canadian operations, is exiting Norway, and plans to spin off its Medical-Surgical unit. Simultaneously, it is expanding its U.S. Oncology Network through acquisitions of PRISM Vision and Core Ventures, adding hundreds of new providers. These moves aim to increase exposure to higher-margin specialty and oncology services while reducing reliance on lower-margin wholesale distribution.

Notably, McKesson’s role in the COVID-19 response was reflected in the collaboration with the U.S. government's COVID-19 vaccine distribution effort, wherein McKesson was selected as the centralized distributor of refrigerated and frozen COVID-19 vaccines and the ancillary kits used to administer those vaccines.

FY26 at a Glance

Revenues in fiscal 2026 were $403.4 billion, up 12% from fiscal 2025, and adjusted EPS was $39.11, up 18% year over year. Segment revenues were led by North American Pharmaceutical at $336.7 billion, followed by Oncology & Multispecialty at $48.4 billion, Medical-Surgical Solutions at $11.5 billion, and Prescription Technology Solutions at $5.8 billion. Segment operating profit margins were 1.09% for North American Pharmaceutical, 2.37% for Oncology & Multispecialty, 17.98% for Prescription Technology Solutions, and 8.15% for Medical-Surgical Solutions.

Bottom Line

Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For McKesson, if you bought shares a decade ago, you're likely feeling really good about your investment today.

According to our calculations, a $1000 investment made in September 2016 would be worth $4,795.36, or a gain of 379.54%, as of September 1, 2026, and this return excludes dividends but includes price increases.

Compare this to the S&P 500's rally of 254.05% and gold's return of 225.98% over the same time frame.

Analysts are forecasting more upside for MCK too.

McKesson combines scale in North American pharmaceutical distribution with faster-growing oncology, multispecialty and biopharma services. Specialty volumes, provider expansion and access solutions continue to broaden the earnings mix, while disciplined capital deployment supports per-share growth. Fiscal 2027 guidance was raised after first-quarter operating profit increased across the core growth platforms. These strengths are balanced by customer concentration, evolving drug-pricing and reimbursement rules, and variability in logistics and Medical-Surgical profitability. The planned separation of Medical-Surgical also adds financing and execution complexity. With durable operating momentum offset by policy, concentration and portfolio-transition risks, the risk-reward profile remains balanced for investors.

Over the past four weeks, shares have rallied 7.03%, and there have been 5 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research